Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ido Sloma"'
Autor:
Friedrich Erhart, Johanna Buchroithner, René Reitermaier, Katrin Fischhuber, Simone Klingenbrunner, Ido Sloma, Dror Hibsh, Renana Kozol, Sol Efroni, Gerda Ricken, Adelheid Wöhrer, Christine Haberler, Johannes Hainfellner, Günther Krumpl, Thomas Felzmann, Alexander M. Dohnal, Christine Marosi, Carmen Visus
Publikováno v:
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recen
Externí odkaz:
https://doaj.org/article/31567993947f492daafe23f1e64695ff
Autor:
Ambikai Gajan, Carly E. Martin, Seongho Kim, Milap Joshi, Sharon K. Michelhaugh, Ido Sloma, Sandeep Mittal, Steven Firestine, Malathy P. V. Shekhar
Publikováno v:
Cells, Vol 8, Iss 11, p 1375 (2019)
Rad6B, a principal component of the translesion synthesis pathway, and activator of canonical Wnt signaling, plays an essential role in cutaneous melanoma development and progression. As Rad6 is encoded by two genes, namely, UBE2A (RAD6A) and UBE2B (
Externí odkaz:
https://doaj.org/article/f94f9d3ec0ce41acac0a76d5dc7d19a0
Autor:
David E. Ochayon, Boris M. Baranovski, Peter Malkin, Ronen Schuster, Noa Kalay, Rotem Ben-Hamo, Ido Sloma, Justin Levinson, Jared Brazg, Sol Efroni, Eli C. Lewis, Uri Nevo
Publikováno v:
Cell Transplantation, Vol 25 (2016)
Immune tolerance toward “self” is critical in multiple immune disorders. While there are several mechanisms to describe the involvement of immune cells in the process, the role of peripheral tissue cells in that context is not yet clear. The theo
Externí odkaz:
https://doaj.org/article/8c074e7b554446628cf5b9dae397d835
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2efa1fb2eca5731e15fb0928e1e7b7
https://doi.org/10.1158/1535-7163.c.6543438.v1
https://doi.org/10.1158/1535-7163.c.6543438.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6636bc7fd14949c096b587e72af567
https://doi.org/10.1158/1535-7163.22522569.v1
https://doi.org/10.1158/1535-7163.22522569.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Data from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a65e018c5371d1a9a5d2dd985a27fdf8
https://doi.org/10.1158/1535-7163.22522572.v1
https://doi.org/10.1158/1535-7163.22522572.v1
Autor:
Gilad Silberberg, Brandon Walling, Amy Wesa, Alessandra Audia, Ido Sloma, Yi Zeng, Guanghui Han, Jia Tang, Paige Pammer
Publikováno v:
Archives of Clinical and Biomedical Research.
Autor:
Dieila Giomo De Lima, Mariana Brait, Laura Palmieri, Fernando T. Zamuner, Esther Broner, Kellie N. Smith, Timothy Westlake, Or Malca, Sol Efroni, Ido Sloma, David Sidransky
Publikováno v:
Cancer Research. 83:2121-2121
Head and neck squamous cell carcinoma (HNSCC) is a global health problem. Successful immunotherapy in HNSCC is currently based on the ability to block the interaction of PD1 and PDL1 and abolish the inhibition of CD8+ T cells, thus enhancing the anti
Autor:
Gilad Silberberg, Brandon Walling, Amy Wesa, Alessandra Audia, Ido Sloma, Yi Zeng, Guanghui Han, Jia Tang, Paige Pammer, A’ishah Bakayoko, Xuan Ren, Daniel Ciznadija, Bandana Vishwakarma, Yaron Mosesson, Marianna Zipeto, Michael Ritchie
Despite considerable progress made in improving therapeutic strategies, the overall survival for patients diagnosed with various cancer types remains low. Further, patients often cycle through multiple therapeutic options before finding an effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c707f615650caa1ede4c0ebad5dba96
https://doi.org/10.1101/2022.06.14.495846
https://doi.org/10.1101/2022.06.14.495846
Autor:
Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, Christopher McCann, Katherine McAllister, Jochen Prehn, Jamie Young, Jess Bateson, Lewis Gallagher, Magali Michaut, Vivek Iyer, Aikaterini Chatzipli, Syd Barthorpe, Daniel Ciznadija, Ido Sloma, Amy Wesa, David A. Tice, Lodewyk Wessels, Mathew Garnett, Daniel B. Longley, Ultan McDermott, Simon S. McDade
Publikováno v:
Grinkevich, V, Wappett, M, Crawford, N, Price, S, Lees, A, McCann, C, McAllister, K A, Prehn, J H, Young, J, Bateson, J H, Gallagher, L, Michaut, M, Iyer, V, Chatzipli, A, Barthorpe, S, Ciznadija, D, Sloma, I, Wesa, A, Tice, D A, Wessels, L F A, Garnet, M, Longley, D B, McDermott, U & McDade, S S 2022, ' Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists ', Molecular Cancer Therapeutics, vol. 21, no. 4, pp. 594-606 . https://doi.org/10.1158/1535-7163.MCT-21-0532
Molecular Cancer Therapeutics, 21(4)
Molecular Cancer Therapeutics, 21(4)
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents: